MoonLake Immunotherapeutics (MLTX) Payables (2020 - 2026)

MoonLake Immunotherapeutics' Payables history runs 7 years deep, the most recent figure standing at $23.4 million for Q1 2026.

• In Q1 2026, Payables rose 94.74% year-over-year to $23.4 million; the TTM figure through Mar 2026 stood at $23.4 million (up 94.74% YoY), while the FY2025 annual figure was $29.6 million, up 228.66% from the prior year.
• Payables for Q1 2026 stood at $23.4 million, down from $29.6 million in the prior quarter.
• The five-year high for Payables was $29.6 million in Q4 2025, with the low at $150000.0 in Q1 2022.
• The 5-year median for Payables is $4.4 million (2023), against an average of $8.9 million.
• The sharpest annual moves came in 2022 and 2023: Payables sank 98.46% in 2022, then surged 2451.6% in 2023.
• MoonLake Immunotherapeutics' Payables stood at $254972.0 in 2022, then surged by 620.74% to $1.8 million in 2023, then jumped by 389.31% to $9.0 million in 2024, then jumped by 228.66% to $29.6 million in 2025, then slipped by 20.89% to $23.4 million in 2026.
• Business Quant data shows MLTX's Payables at $23.4 million in Q1 2026, $29.6 million in Q4 2025, and $25.3 million in Q3 2025.